Michael Stadiem
Family Medicine · Cary, NCNPI 1750342168
Payments from drug & device makers
Across 359 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$637
- Lilly USA, LLC$512
- AbbVie$485
- GSK$357
- Amgen$204
- plus $2K from 37 others
What the payments were for
- Food & beverage$6,455100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GVOKE HYPOPEN$122
- FARXIGA$122
- TRELEGY ELLIPTA$113
- Ozempic$100
How this compares
$6,455 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 64 | $93,154 |
| FarxigaDapagliflozin Propanediol | 23 | $28,682 |
| TrulicityDulaglutide | 13 | $28,295 |
| EliquisApixaban | 19 | $16,125 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $10,262 |
| TrintellixVortioxetine Hydrobromide | 13 | $5,725 |
| SynthroidLevothyroxine Sodium | 19 | $1,665 |
| Duloxetine Hcl | 37 | $1,015 |
| Rosuvastatin Calcium | 80 | $879 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 36 | $857 |
| Nebivolol Hcl | 12 | $855 |
| Levothyroxine Sodium | 86 | $850 |
| Esomeprazole Magnesium | 15 | $814 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $696 |
| Olmesartan Medoxomil | 29 | $692 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,075 | $93,15464 claims |
| AstraZenecaFarxiga | $637 | $28,68223 claims |
| Lilly USA, LLCTrulicity | $512 | $28,29513 claims |
| PfizerEliquis | $135 | $16,12519 claims |
| GSKTrelegy Ellipta | $357 | $10,26214 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $138 | $5,72513 claims |
| AbbVieSynthroid | $485 | $1,66519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Cary
- Mrinalini KodumagullaCary$283K
- Christopher ChaoCary$201K
- James BlountCary$72K
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.